News Image

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025

Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025

Read more at globenewswire.com

DESIGN THERAPEUTICS INC

NASDAQ:DSGN (2/11/2025, 3:11:59 PM)

3.79

-0.47 (-11.03%)

DSGN Latest News and Analysis

ChartMill News Imagea day ago - ChartmillMonday's pre-market session: top gainers and losers

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Follow ChartMill for more